China Oncology ›› 2023, Vol. 33 ›› Issue (5): 517-526.doi: 10.19401/j.cnki.1007-3639.2023.05.012

• Review • Previous Articles     Next Articles

Advances in fatty acid metabolism reprogramming of lung cancer

WU Jing(), ZHOU Juan, SU Chunxia()   

  1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China
  • Received:2022-06-21 Revised:2022-09-05 Online:2023-05-30 Published:2023-06-16
  • Contact: SU Chunxia

Abstract:

Lung cancer is the most common malignant tumor and the leading cause of cancer-related mortality. Although the development of targeted therapy and immunotherapy has significantly improved the efficacy and prognosis of lung cancer patients, the overall 5-year survival rate is still lower than 20%. Therefore, in-depth exploration of the pathogenesis of lung cancer has important clinical significance for the development of new diagnosis and treatment strategies and further improvement of patient survival. Metabolic reprogramming is a crucial way for tumors to maintain malignant biological behavior. Previous studies have shown that fatty acid metabolism reprogramming has profound effects on tumorigenesis and progression of lung cancer, suggesting that targeting lung cancer fatty acid metabolism might be an important direction for the development of new anti-tumor regimens. This paper, focusing on the reprogramming of fatty acid metabolism, reviewed the relationship between fatty acid metabolism and lung cancer progression from the aspects of the key protein molecules involved in each procedure of fatty acid metabolism (including uptake, synthesis, storage and decomposition), and discussed the application status and challenges of anti-tumor therapy targeting fatty acid metabolism, expecting to provide clues and insights for the development of novel treatment regimen for lung cancer.

Key words: Lung cancer, Fatty acid metabolism, Reprogram, Targeted therapy

CLC Number: